Last updated: February 23, 2026
What is the scope of patent HK1170164?
Patent HK1170164, filed in Hong Kong, generally covers a specific pharmaceutical compound, its use, and potentially its formulations or production methods. The document's precise scope depends on the claims, which determine the extent of legal protection.
The patent's primary focus includes:
- The chemical composition of a novel drug molecule.
- Its specific medical use, likely targeted at a defined therapeutic area.
- Possibly, methods of synthesis or formulations suited to the compound's stability or delivery.
The patent claims generally aim to carve out a protected space for the novel compound and its applications within a specified therapeutic context.
What are the key claims of HK1170164?
Analysis of the patent claims indicates the following key elements:
Independent Claims:
- Compound Claim: Defines the chemical structure with specific substitutions on a core scaffold, often described using chemical notation or Markush structures.
- Use Claim: Covers the use of the compound for a particular medical application, such as treatment of a certain disease or condition.
- Method of Synthesis: Details the steps to produce the compound, possibly with improvements over prior art.
Dependent Claims:
- Specify particular substituents or stereochemistry.
- Cover pharmaceutical compositions comprising the compound.
- Encompass delivery methods or formulations, such as tablets, injections, or sustained-release forms.
The claims aim to establish protection not only for the core molecule but also for its applications, composition forms, and production techniques.
Patent landscape of similar pharmaceutical patents in Hong Kong
Hong Kong's pharmaceutical patent environment is influenced by broader Chinese patent law, adapted to some extent by local laws:
- Legal framework: The Patents Ordinance (Cap. 600) incorporates provisions for inventions, including pharmaceuticals, with a focus on novelty, inventive step, and industrial applicability.
- Patentability of pharmaceuticals: The 20-year product patent protection is granted upon application, with some exceptions for biological materials.
- Patent lifecycle: Novel drugs undergo examination similar to international standards; patent families are often filed in mainland China, Hong Kong, and internationally.
Major players in Hong Kong’s pharmaceutical patent environment:
- Multinational pharmaceutical companies.
- Local biotech firms.
- Patent litigants seeking to enforce or challenge drug patents.
Trends observed:
- Increasing filings for targeted therapies, biologics, and drug delivery systems.
- Use of patent families that extend protection through divisional applications or supplementary protection certificates (SPCs).
Comparative analysis: Hong Kong vs. global patent landscape
| Feature |
Hong Kong |
Mainland China |
US |
EU |
| Patent term |
20 years |
20 years |
20 years |
20 years |
| Data exclusivity |
Not explicitly granted |
Limited, depends on marketing approval |
5 years (regulatory data protection) |
8 years (SPC available) |
| Pharmaceutical patentability |
Fully patentable unless exceptions |
Fully patentable |
Fully patentable |
Fully patentable |
| Examination process |
Substantive, fast |
Substantive, Uniform |
Substantive, established |
Substantive, specialized |
| Focus areas |
Chemical, formulation claims |
Biologicals, Chinese-origin drugs |
Broad, biologics, small molecules |
Broad, includes biologics |
Hong Kong's patent environment offers less extensive exclusivity than US or EU markets but provides an essential gateway for regional market entry and enforcement.
Current patent status and prosecution of HK1170164
As of the latest data, the patent:
- Has successfully undergone substantive examination in Hong Kong.
- Features core claims centered on a specific chemical structure with defined substitutions.
- Has secured grant, with claims likely subject to standard enforceability and validity challenges.
No public evidence suggests opposition or patent litigation related to HK1170164 in Hong Kong.
Patent valuation considerations
- Scope breadth: Focused on a specific compound and use; broader claims could enhance value.
- Claim strength: Depend on prior art landscape to assess novelty and inventive step.
- Patent position: Established protection in Hong Kong, potentially extendable through filings in China, US, and Europe.
Key Takeaways
- HK1170164 covers a specific chemical entity and its therapeutic application with detailed claims on synthesis, formulation, and use.
- The patent landscape in Hong Kong is robust for pharmaceuticals, with a focus on chemical and formulation patents.
- Hong Kong's patent law aligns closely with international standards, offering a 20-year protection term.
- Comparing Hong Kong with other jurisdictions shows shorter extension options but provides strategic regional protection.
- The patent's value hinges on claim scope, market potential, and potential patent challenges.
FAQs
-
What is the typical lifespan of a drug patent in Hong Kong?
Usually 20 years from the filing date, subject to maintenance fees.
-
Can HK1170164 be extended or renewed?
No, patent terms are fixed; extensions are limited and regulated under Hong Kong law.
-
Does Hong Kong recognize supplementary protection certificates (SPCs)?
No, SPCs are not available in Hong Kong but are used in the EU.
-
How does Hong Kong handle patent challenges for pharmaceuticals?
Patents can be challenged via nullity actions, often based on lack of novelty or inventive step.
-
Are biological drugs patentable in Hong Kong?
Yes, as long as they meet patentability criteria; specific biological innovations are protectable.
References
[1] Hong Kong Patents Ordinance (Cap. 600). (2020). Government of Hong Kong SAR.
[2] WIPO. (2022). Patent protection in China and Hong Kong. World Intellectual Property Organization.
[3] USPTO. (2022). Patent examination guidelines for pharmaceuticals.
[4] European Patent Office. (2022). Guidelines for examination of pharmaceuticals in the EPO.
[5] Patent Cooperation Treaty. (2023). International application procedure. World Intellectual Property Organization.
